Here we provide highlights of our progress and achievements during the year.

As we bid farewell to 2023, we reflect on another successful year with some significant milestones.

We are proud to have extended our Series B financing by £10M to £85.5M, welcoming British Patient Capital as a new investor. Our latest round of financing has enabled us to advance our pre-clinical pipeline of new and existing targets, with an aim of ultimately improving the lives of patients with rare disease and immunological conditions. We continued to advance our MC2 program for congenital adrenal hyperplasia and ACTH dependent Cushing’s towards the clinic, advancing GPR65 and SLC15A4 to lead optimisation and adding cGAS as a new target.

After nearly a year of planning, we successfully moved to our new purpose built flagship facility on the ARC Oxford Campus in the Spring of 2023. In addition to co-locating our existing Mass Spec, Protein biochemistry and Pharmacology teams, the additional space enabled us to build new chemistry and structural biology labs. As the company and pipeline matures, we have expanded our leadership team to include Winfried Barchet as VP of Immunology, Julia Sampson as VP of Non-clinical Development and Melissa Faris as Chief Business Officer. We are also delighted to have welcomed Jim Geraghty as Independent Chair of our Board of Directors.

We were proud to win the OXBA Oxfordshire Business Awards Employer of The Year Award, to be shortlisted for several local and international awards this year, and to have been included in PwC’s list of Future 50 in the UK life sciences industry.

Being on the same site has brought new energy to the team as we are able to not just solve problems in person but to have fun together. We love having a kitchen big enough for table tennis leagues, all hands meetings, parties and OMass band live gigs. With the OMass Story now up on our wall, our purpose is clear: to deliver new medicines to patients, to build Britain’s Big Biotech and to have fun together on the journey ahead.